Tech Company Financing Transactions
ashibio Funding Round
ashibio, based in Brisbane, secured $40 million in funding from MPM Capital, Agent Capital and Mirae Asset Venture Investment.
Transaction Overview
Company Name
Announced On
6/20/2024
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to continue to advance development of several investigative therapies including a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease characterized by severe and progressive heterotopic ossification (HO), a pathological condition that causes abnormal bone formation in muscles, tendons, ligaments and other soft tissues.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
2000 Sierra Point Parkway 701
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
Email Address
Overview
ashibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Pankaj Bhargava
Browse more venture capital transactions:
Prev: 6/20/2024: Pomerium venture capital transaction
Next: 6/20/2024: Slay venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs